surmount 3 tirzepatide being discontinued Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase trial ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide

Patients with a history of gastrointestinal disorders, including inflammatory bowel disease, gastroparesis, or previous pancreatitis, should maintain closer communication with their healthcare provider throughout Zepbound treatment, as they may be at higher risk for complications

@teamallmax GET YOURS NOW

Angiotensin II type 2 receptor (AT2R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons

Weir for their contribution to the peer review of this work

Approved by the FDA in 2022 for the treatment of type 2 diabetes, its a weekly injection thats proven so effective for weight loss that its been fast-tracked by the FDA for approval for treating obesity but has not been given the green light just yet